title: [Surgical treatment for gastrointestinal stromal tumor].
abstract: OBJECTIVE
  To analyze the effects of surgical treatment for gastrointestinal stromal tumors (GISTs) and influential factors of survival.
  
  
  METHODS
  The clinical data and the tissue slices including immunohistochemical staining of 153 cases of GISTs from January 1990 to March 2006 were rechecked retrospectively. All patients were followed up carefully. More attention was paid to the surgical effects and the influential factors of survival.
  
  
  RESULTS
  The overall survival rates at 1-, 2-, 3-, 4- and 5-year were 94.9%, 83.3%, 73.3%, 70.5% and 64.3%, respectively. The median survival time for patients with tumor resected completely was 66.0 months, and the 2- and 5-year survival rate were 89.4% and 70.9% respectively. The median survival time was 23.8 months for the patients with tumor resected partly, and only two of these patients survived over 2 years. Gender, tumor sites, preoperative metastasis, tumor size, pathological type, karyokinesis and recurrence and metastasis were related with survival rates for the patients with tumor resected completely on univariate analysis, but tumor size, pathology type, recurrence and metastasis were related with survival rates on Cox regression multivariate analysis (P < 0.05).
  
  
  CONCLUSIONS
  Surgery should still be the main therapy for GISTs. Local complete resection is the principal treatment. The survival cannot be improved by extensive resection and lymph nodes clearance.
authors.affiliation: Department of Abdominal Surgery, Cancer Center, Sun Yat-sen University, State Key Laboratory of Oncology in Southern China, Guangzhou 510060, China. wds@medmail.com.cn
authors.forename: De-Sen
authors.initials: DS
authors.lastname: Wan
authors.forename: Xiao-Jun
authors.initials: XJ
authors.lastname: Wu
authors.forename: Pei-Rong
authors.initials: PR
authors.lastname: Ding
authors.forename: Zhi-Zhong
authors.initials: ZZ
authors.lastname: Pan
authors.forename: Zhi-Wei
authors.initials: ZW
authors.lastname: Zhou
authors.forename: Gong
authors.initials: G
authors.lastname: Chen
authors.forename: Li-Ren
authors.initials: LR
authors.lastname: Li
authors.forename: Zhen-Hai
authors.initials: ZH
authors.lastname: Lu
authors.forename: Ling-Heng
authors.initials: LH
authors.lastname: Kong
authors.forename: Xiao-Man
authors.initials: XM
authors.lastname: Liang
authors.forename: Rong-Zhen
authors.initials: RZ
authors.lastname: Luo
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D018952:Antigens, CD34 / Q000032:analysis*; D005260:Female; D005500:Follow-Up Studies; D046152:Gastrointestinal Stromal Tumors / Q000378:metabolism / Q000401:mortality / Q000601:surgery*; D006801:Humans; D007150:Immunohistochemistry; D053208:Kaplan-Meier Estimate; D008297:Male; D008875:Middle Aged; D019009:Proto-Oncogene Proteins c-kit / Q000032:analysis*; D012189:Retrospective Studies; D015996:Survival Rate; D016896:Treatment Outcome
chemical_list: D018952:Antigens, CD34; D019009:Proto-Oncogene Proteins c-kit